Clinical Trial Update: Immune Responses in Patients Treated With Raltegravir [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immune responses in patients treated with raltegravir has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Raltegravir (raltegravir)

Snippet

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Conditions: HIV Infections | Phase 3 | Status: WITHDRAWN